Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 67
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
J Pharmacol Exp Ther ; 371(1): 25-35, 2019 10.
Artículo en Inglés | MEDLINE | ID: mdl-31375638

RESUMEN

Methylcellulose (MC; 0.5% concentration) is commonly used when evaluating investigational agents for efficacy in preclinical models of disease. When administered by the oral (PO) route, MC is considered a Food and Drug Administration "generally recognized as safe" compound. Yet, there is limited data pertaining to the tolerability and impact on model fidelity of repeated intraperitoneal administration of 0.5% MC. Chronic administration of high-concentration MC (2%-2.5%) has been used to induce anemia, splenomegaly, and lesions in multiple organ systems in several preclinical species. Histopathological findings from a diagnostic pathologic analysis of a single mouse from our laboratory with experimentally induced chronic seizures that had received repeated intraperitoneal administration of antiseizure drugs delivered in MC revealed similar widespread lesions. This study thus tested the hypothesis that chronic administration of intraperitoneal, but not PO, MC incites histologic lesions without effects on preclinical phenotype. Male CF-1 mice (n = 2-14/group) were randomized to receive either 6 weeks of twice weekly 0.5% MC or saline (intraperitoneal or PO) following induction of chronic seizures. Histology of a subset of mice revealed lesions in kidney, liver, mediastinal lymph nodes, mesentery, aorta, and choroid plexus only in intraperitoneal MC-treated mice (n = 7/7). Kindled mice that received MC PO (n = 5) or saline (intraperitoneal n = 6, PO n = 3) had no lesions. There were no effects of intraperitoneal MC treatment on body weight, appearance, seizure stability, or behavior. Nonetheless, our findings suggest that repeated intraperitoneal, but not PO, MC elicits systemic organ damage without impacting the model phenotype, which may confound interpretation of investigational drug-induced histologic lesions. SIGNIFICANCE STATEMENT: Methylcellulose (0.5% concentration) is commonly used when evaluating investigational agents for efficacy in preclinical models of disease. Herein, we demonstrate that repeated administration of 0.5% methylcellulose by the intraperitoneal, but not oral, route results in systemic inflammation and presence of foam-laden macrophages but does not impact the behavioral phenotype of a rodent model of neurological disease.


Asunto(s)
Inyecciones Intraperitoneales/efectos adversos , Metilcelulosa/efectos adversos , Fenotipo , Convulsiones/inducido químicamente , Animales , Aorta/efectos de los fármacos , Plexo Coroideo/efectos de los fármacos , Evaluación Preclínica de Medicamentos/métodos , Evaluación Preclínica de Medicamentos/normas , Femenino , Riñón/efectos de los fármacos , Hígado/efectos de los fármacos , Ganglios Linfáticos/efectos de los fármacos , Masculino , Metilcelulosa/administración & dosificación , Metilcelulosa/toxicidad , Ratones , Ratones Endogámicos C57BL
2.
BMC Cancer ; 19(1): 424, 2019 May 07.
Artículo en Inglés | MEDLINE | ID: mdl-31064330

RESUMEN

BACKGROUND: pressurized intraperitoneal aerosol chemotherapy (PIPAC), with or without electrostatic precipitation (ePIPAC), was recently introduced in the treatment of peritoneal metastases (PM) from ovarian cancer (OC). Preliminary clinical data are promising, but several methodological issues as well the anticancer efficacy of PIPAC remain unaddressed. Here, we propose a rat ePIPAC model that allows to study these issues in a clinically relevant, reproducible, and high throughput model. METHODS: laparoscopy and PIPAC were established in healthy Wistar rats. Aerosol properties were measured using laser diffraction spectrometry based granulometric analyses. Electrostatic precipitation was accomplished using a commercially available generator (Ultravision™). A xenograft model of ovarian PM was created in athymic rats using intraperitoneal (IP) injection of SKOV-3 luciferase positive cells. Tumor growth was monitored weekly by in vivo bioluminescence imaging. RESULTS: PIPAC and electrostatic precipitation were well tolerated using a capnoperitoneum of 8 mmHg. All rats survived the (e)PIPAC procedure and no gas or aerosol leakage was observed over the entire procedure. With an injection pressure of 20 bar, granulometry showed a mean droplet diameter (D(v,0.5)) of 47 µm with a flow rate of 0.5 mL/s, and a significantly lower diameter (30 µm) when a flow rate of 0.8 mL/s was used. Experiments using IP injection of SKOV-3 luciferase positive cells showed that after IP injection of 20 × 106 cells, miliary PM was observed in all animals. PIPAC was feasible and well supported in these tumor bearing animals. CONCLUSIONS: we propose a reproducible and efficient rodent model to study PIPAC and ePIPAC in OC xenografts with widespread PM. This model allows to characterize and optimize pharmacokinetic and biophysical parameters, and to evaluate the anti-cancer efficacy of (e)PIPAC treatment.


Asunto(s)
Antineoplásicos/administración & dosificación , Laparoscopía/métodos , Neoplasias Ováricas/terapia , Neoplasias Peritoneales/terapia , Ensayos Antitumor por Modelo de Xenoinjerto/métodos , Aerosoles/administración & dosificación , Animales , Línea Celular Tumoral , Terapia Combinada/efectos adversos , Terapia Combinada/métodos , Femenino , Humanos , Inyecciones Intraperitoneales/efectos adversos , Inyecciones Intraperitoneales/métodos , Neoplasias Ováricas/patología , Neoplasias Peritoneales/patología , Neoplasias Peritoneales/secundario , Peritoneo/efectos de los fármacos , Peritoneo/patología , Presión , Ratas , Ratas Desnudas , Ratas Wistar , Electricidad Estática
3.
J Fish Dis ; 40(12): 1805-1813, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-28548686

RESUMEN

Atlantic lumpfish (Cyclopterus lumpus L.) is used as a biological delousing agent for sea lice (Lepeophtheirus salmonis K.) infestations in Norwegian aquaculture. Here, we present a study on the antibody response and vaccine side effects after intramuscular and intraperitoneal injection of lumpfish with two vaccines. Both vaccines contained bacterial antigens from atypical Aeromonas salmonicida A-layer types V and VI, Vibrio anguillarum serotype O1 and Moritella viscosa sp., but one vaccine contained a vegetable oil-based adjuvant, while the other contained a mineral oil-based adjuvant. Intramuscular injection of the mineral oil-based vaccine caused a high acute mortality of fish within 48 hr after immunization. Intraperitoneal injection of the mineral oil-based vaccine resulted in a lower severity of intra-abdominal side effects than the vegetable oil-based vaccine. Intramuscular injection of the mineral oil-based vaccine resulted in a significantly higher antibody response against A. salmonicida when compared to controls and the vegetable oil-based vaccine group. The antibody response was poor against V. anguillarum and M. viscosa for all groups. Our results indicate that intramuscular injection of oil-based vaccines might be feasible for providing immunological protection for Atlantic lumpfish against bacterial diseases, especially atypical A. salmonicida, but more work is required to identity optimal adjuvants.


Asunto(s)
Formación de Anticuerpos/efectos de los fármacos , Enfermedades de los Peces/prevención & control , Infecciones por Bacterias Gramnegativas/veterinaria , Perciformes , Vacunación/veterinaria , Adyuvantes Inmunológicos/administración & dosificación , Adyuvantes Inmunológicos/efectos adversos , Animales , Acuicultura/métodos , Vacunas Bacterianas/inmunología , Enfermedades de los Peces/inmunología , Enfermedades de los Peces/microbiología , Infecciones por Bacterias Gramnegativas/prevención & control , Bacilos Gramnegativos Anaerobios Facultativos/inmunología , Inyecciones Intramusculares/efectos adversos , Inyecciones Intramusculares/veterinaria , Inyecciones Intraperitoneales/efectos adversos , Inyecciones Intraperitoneales/veterinaria , Aceite Mineral/farmacología , Aceites de Plantas/farmacocinética , Vacunación/efectos adversos
4.
Muscle Nerve ; 43(1): 94-102, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21171100

RESUMEN

Doxorubicin is a chemotherapeutic agent prescribed for a variety of tumors. While undergoing treatment, patients exhibit frequent symptoms that suggest respiratory muscle weakness. Cancer patients can receive doxorubicin chemotherapy through either intravenous (IV) or intraperitoneal (IP) injections. We hypothesized that respiratory muscle function would be depressed in a murine model of chemotherapy. We tested this hypothesis by treating C57BL/6 mice with a clinical dose of doxorubicin (20 mg/kg) via IV or IP injection. Three days later we measured contractile properties of muscle fiber bundles isolated from the diaphragm. Doxorubicin consistently depressed diaphragm force with both methods of administration (P < 0.01). Doxorubicin IP exaggerated the depression in diaphragm force and stimulated tissue inflammation and muscle fiber injury. These results suggest that clinically relevant doses of doxorubicin cause respiratory muscle weakness and that the loss of function depends, in part, on the route of administration.


Asunto(s)
Antibióticos Antineoplásicos/toxicidad , Diafragma/efectos de los fármacos , Modelos Animales de Enfermedad , Doxorrubicina/toxicidad , Debilidad Muscular/inducido químicamente , Parálisis Respiratoria/inducido químicamente , Animales , Diafragma/patología , Diafragma/fisiopatología , Inyecciones Intraperitoneales/efectos adversos , Inyecciones Intravenosas/efectos adversos , Masculino , Ratones , Ratones Endogámicos C57BL , Debilidad Muscular/patología , Debilidad Muscular/fisiopatología , Parálisis Respiratoria/patología , Parálisis Respiratoria/fisiopatología
5.
Int J Gynecol Cancer ; 21(5): 811-5, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21412160

RESUMEN

OBJECTIVE: To determine the prevalence of grade 3 or 4 toxicity associated with intraperitoneal (IP) chemotherapy subsequent to primary surgical debulking compared to post-neoadjuvant chemotherapy and interval debulking in advanced ovarian cancer. METHODS: Patients receiving IP chemotherapy from 2006 to 2010 were reviewed. Study cohort was stratified by initial treatment (upfront surgery vs neoadjuvant chemotherapy). The National Cancer Institute toxicity grading scale was used to assess treatment-related toxicities immediately before each cycle. The χ² test was used to check for association between categorical variables. RESULTS: Thirty-three patients received IP chemotherapy after optimal debulking. Sixteen patients had upfront surgery. The total number of IP chemotherapy cycles administered was 134. Significantly, more patients treated with IP chemotherapy after intravenous neoadjuvant chemotherapy experienced fatigue (P=0.038) compared to those treated after upfront surgery. During the course of IP regimen, the patients having upfront surgery tended to experience more grade 3/4 hematologic toxicities (P=0.06) and abdominal pain (P=0.08). Twenty-four (73%) of 33 patients completed all prescribed IP chemotherapy cycles. There was no significant difference between the 2 groups in need for dose reduction or delays, use of paclitaxel on day 8, neurologic/gastrointestinal/metabolic toxicities, and IP port complications. CONCLUSIONS: Intraperitoneal chemotherapy can be given after optimal primary surgery or interval surgery after neoadjuvant chemotherapy with similar toxicity profile. Toxicity data can be used to plan for optimal IP chemotherapy delivery, patient counseling, and ongoing supportive care.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Carcinoma/tratamiento farmacológico , Carcinoma/cirugía , Procedimientos Quirúrgicos Ginecológicos/métodos , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Ováricas/cirugía , Carcinoma/epidemiología , Carcinoma/patología , Quimioterapia Adyuvante/efectos adversos , Terapia Combinada , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/clasificación , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Femenino , Humanos , Inyecciones Intraperitoneales/efectos adversos , Persona de Mediana Edad , Terapia Neoadyuvante , Neoplasias Ováricas/epidemiología , Neoplasias Ováricas/patología , Prevalencia , Estudios Retrospectivos
6.
Mol Cancer Res ; 19(2): 288-300, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-33139505

RESUMEN

Oil is frequently used as a solvent to inject lipophilic substances into the peritoneum of laboratory animals. Although mineral oil causes chronic peritoneal inflammation, little is known whether other oils are better suited. We show that olive, peanut, corn, or mineral oil causes xanthogranulomatous inflammation with depletion of resident peritoneal macrophages. However, there were striking differences in the severity of the inflammatory response. Peanut and mineral oil caused severe chronic inflammation with persistent neutrophil and monocyte recruitment, expansion of the vasculature, and fibrosis. Corn and olive oil provoked no or only mild signs of chronic inflammation. Mechanistically, the vegetal oils were taken up by macrophages leading to foam cell formation and induction of cell death. Olive oil triggered caspase-3 cleavage and apoptosis, which facilitate the resolution of inflammation. Peanut oil and, to a lesser degree, corn oil, triggered caspase-1 activation and macrophage pyroptosis, which impair the resolution of inflammation. As such, intraperitoneal oil administration can interfere with the outcome of subsequent experiments. As a proof of principle, intraperitoneal peanut oil injection was compared with its oral delivery in a thioglycolate-induced peritonitis model. The chronic peritoneal inflammation due to peanut oil injection impeded the proper recruitment of macrophages and the resolution of inflammation in this peritonitis model. In summary, the data indicate that it is advisable to deliver lipophilic substances, like tamoxifen, by oral gavage instead of intraperitoneal injection. IMPLICATIONS: This work contributes to the reproducibility of animal research by helping to understand some of the undesired effects observed in animal experiments.


Asunto(s)
Aceite de Maíz/efectos adversos , Inflamación/inducido químicamente , Inyecciones Intraperitoneales/efectos adversos , Macrófagos Peritoneales/metabolismo , Animales , Femenino , Humanos , Ratones , Modelos Animales
7.
Exp Biol Med (Maywood) ; 246(14): 1668-1679, 2021 07.
Artículo en Inglés | MEDLINE | ID: mdl-33794699

RESUMEN

Intrauterine growth restriction affects up to 10% of all pregnancies, leading to fetal programming with detrimental consequences for lifelong health. However, no therapeutic strategies have so far been effective to ameliorate these consequences. Our previous study has demonstrated that a single dose of nutrients administered into the amniotic cavity, bypassing the often dysfunctional placenta via intra-amniotic administration, improved survival at birth but not birthweight in an intrauterine growth restriction rabbit model. The aim of this study was to further develop an effective strategy for intra-amniotic fetal therapy in an animal model. Intrauterine growth restriction was induced by selective ligation of uteroplacental vessels on one uterine horn of pregnant rabbits at gestational day 25, and fetuses were delivered by cesarean section on GD30. During the five days of intrauterine growth restriction development, three different methods of intra-amniotic administration were used: continuous intra-amniotic infusion by osmotic pump, multiple intra-amniotic injections, and single fetal intraperitoneal injection. Technical feasibility, capability to systematically reach the fetus, and survival and birthweight of the derived offspring were evaluated for each technique. Continuous intra-amniotic infusion by osmotic pump was not feasible owing to the high occurrence of catheter displacement and amnion rupture, while methods using two intra-amniotic injections and one fetal intraperitoneal injection were technically feasible but compromised fetal survival. Taking into account all the numerous factors affecting intra-amniotic fetal therapy in the intrauterine growth restriction rabbit model, we conclude that an optimal therapeutic strategy with low technical failure and positive fetal impact on both survival and birthweight still needs to be found.


Asunto(s)
Retardo del Crecimiento Fetal/dietoterapia , Terapias Fetales/instrumentación , Nutrientes/administración & dosificación , Terapia Nutricional/instrumentación , Líquido Amniótico/metabolismo , Animales , Peso al Nacer , Catéteres/efectos adversos , Femenino , Retardo del Crecimiento Fetal/tratamiento farmacológico , Terapias Fetales/métodos , Bombas de Infusión/efectos adversos , Inyecciones Intraperitoneales/efectos adversos , Terapia Nutricional/métodos , Conejos
8.
Zhonghua Yi Xue Za Zhi ; 90(17): 1177-80, 2010 May 04.
Artículo en Zh | MEDLINE | ID: mdl-20646563

RESUMEN

OBJECTIVE: To evaluate the differences of clinical efficacy between intraperitoneal and intravenous chemotherapy. METHODS: The literature database was extensively searched to retrieve the randomized controlled trials with a relevance of study goal. The strict inclusion and exclusion criteria were formulated. And the original studies were selected. After a quality evaluation, the data were extracted. The Cochrane collaboration Revman 4.2 version software was used for meta-analysis. RESULTS: Five clinical studies were included and there were a total of 1 229 eligible patients. Intraperitoneal chemotherapy and intravenous chemotherapy groups were compared: (1) 2 and 3-year progression-free survival (PFS) increased, 2, 3 and 5-year overall survival (OS) increased. The difference was significant enough so that definite conclusions could be drawn; (2) Among the six indicators of unpleasant chemotherapeutic effects (leucopenia, anemia, thrombopenia, GI tract reactions, neurotoxicity and fever), the occurrence of gastrointestinal reaction increased. The difference was significant enough so that definite conclusions could be drawn. And the remaining five indicators had no statistical significance so that definite conclusions could not be drawn. CONCLUSIONS: For patients with epithelial ovarian cancer (Stages FIGOII-IV) undergoing previously a satisfactory tumor reduction surgery (postoperative residual lesions < 1 to 2 cm), intraperitoneal chemotherapy can improve their 2 and 3-year PFS rates and the 2, 3 and 5-year OS rates; Intraperitoneal chemotherapy has not reduced the side effects. But there is an elevated occurrence of gastrointestinal reactions.


Asunto(s)
Carcinoma/tratamiento farmacológico , Quimioterapia Adyuvante/métodos , Neoplasias Ováricas/tratamiento farmacológico , Quimioterapia Adyuvante/efectos adversos , Femenino , Humanos , Inyecciones Intraperitoneales/efectos adversos , Inyecciones Intravenosas/efectos adversos , Resultado del Tratamiento
9.
Gynecol Oncol ; 114(1): 42-7, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19398124

RESUMEN

OBJECTIVES: Intraperitoneal (IP) chemotherapy has not been widely accepted in the treatment of ovarian cancer. One of the main reasons is the lack of a convenient and safe way to deliver IP therapy. The objective of this study was to investigate the feasibility of delivering IP chemotherapy via direct puncture using a peripheral venous needle, as well as evaluating the associated risk factors and complications in the primary treatment of ovarian, fallopian tube, and primary peritoneal cancer. METHODS: The clinical records of all patients with stage II-IV epithelial ovarian, fallopian tube, and primary peritoneal cancer at Sun Yat-sen University Cancer Center from 01/1995 to 11/2006 were reviewed retrospectively to identify patients who had received IP therapy via direct puncture after primary cytoreduction. RESULTS: We identified 194 patients, and 121 (62.4%) of them successfully completed six or more cycles of IP chemotherapy, whereas 73 (37.6%) failed. Two (1%) patients ceased IP therapy directly due to IP access related complications and 35 (18.1%) discontinued IP therapy for reasons unrelated to IP access. Old age might be a potential risk factor for IP therapy failure. The IP therapy failure rate in patients over 60 years old was higher than that in patients under or at 60 (57.1% versus 34.3%, P=0.021). Body mass index were not associated with IP therapy failure. CONCLUSIONS: IP access via direct puncture using a peripheral venous needle could be an alternative and safe way to deliver IP chemotherapy in the primary treatment of ovarian cancer.


Asunto(s)
Neoplasias de las Trompas Uterinas/tratamiento farmacológico , Infusiones Parenterales/métodos , Inyecciones Intraperitoneales/métodos , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Peritoneales/tratamiento farmacológico , Punciones/métodos , Adulto , Anciano , Terapia Combinada , Neoplasias de las Trompas Uterinas/patología , Neoplasias de las Trompas Uterinas/cirugía , Estudios de Factibilidad , Femenino , Humanos , Infusiones Parenterales/efectos adversos , Inyecciones Intraperitoneales/efectos adversos , Persona de Mediana Edad , Estadificación de Neoplasias , Neoplasias Ováricas/patología , Neoplasias Ováricas/cirugía , Neoplasias Peritoneales/patología , Neoplasias Peritoneales/cirugía , Estudios Retrospectivos , Insuficiencia del Tratamiento , Resultado del Tratamiento , Adulto Joven
10.
J Am Assoc Lab Anim Sci ; 58(3): 373-379, 2019 05 01.
Artículo en Inglés | MEDLINE | ID: mdl-30857577

RESUMEN

The AVMA Guidelines for the Euthanasia of Animals considers injection of barbiturates to be an acceptable method of euthanasia in rodents but states there is a potential for pain when administered intraperitoneally. This study examined the potential for pain in mice by assessing visceral pain after intraperitoneal administration and acute pain by using a paw-lick test. Male and female mice (n = 160) intraperitoneally received a euthanizing dose of sodium pentobarbital at a concentration of 5, 50, or 390 mg/mL and were observed for writhing, peritoneum-directed behaviors (PDB), loss of righting reflex, and time to death. Writhing was not observed in any animal. There was no significant difference in the number of mice exhibiting PDB or in the rate of PDB for responders receiving either saline or the 390-mg/mL solution. There was a significant treatment effect on time, with greater concentration and dose resulting in more rapid loss of righting reflex and death. In the second set of experiments, the same solutions were injected subcutaneously into the plantar hindpaw of male and female mice (n = 84). The number of responders, latency until the first lick, and the number of licks per responder were recorded. The number of responders was increased in the 50-mg/mL group; however, there was no difference in latency or the number of licks per responder. These results show that intraperitoneal injection of sodium pentobarbital for euthanasia in mice did not result in increased behavioral signs of pain, and animals lose consciousness more rapidly than the onset of pain seen in the pawlick test. Therefore, although sodium pentobarbital is capable of inducing inflammation, euthanasia through intraperitoneal administration is rapid and does not result in overt signs of pain when compared with injection of saline.


Asunto(s)
Hipnóticos y Sedantes/efectos adversos , Dolor/veterinaria , Pentobarbital/efectos adversos , Animales , Eutanasia Animal/métodos , Femenino , Hipnóticos y Sedantes/administración & dosificación , Inyecciones Intraperitoneales/efectos adversos , Inyecciones Intraperitoneales/veterinaria , Ciencia de los Animales de Laboratorio , Masculino , Ratones , Dolor/inducido químicamente , Dimensión del Dolor , Pentobarbital/administración & dosificación
11.
Perit Dial Int ; 28(3): 229-31, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18474912

RESUMEN

Chylous ascites is a rare complication in patients undergoing peritoneal dialysis. It may occur due to traumatic peritoneal dialysis catheter insertion or other causes. It is important to be aware of this condition as it may be confused with peritonitis, and antibiotics may be inappropriately administered. We report a case of chylous ascites occurring after catheter insertion and discuss management of this condition.


Asunto(s)
Ascitis Quilosa/etiología , Fallo Renal Crónico/terapia , Diálisis Peritoneal/efectos adversos , Adulto , Ascitis Quilosa/diagnóstico , Diagnóstico Diferencial , Gentamicinas/uso terapéutico , Humanos , Inyecciones Intraperitoneales/efectos adversos , Fallo Renal Crónico/complicaciones , Masculino , Peritonitis/diagnóstico , Peritonitis/tratamiento farmacológico , Vancomicina/uso terapéutico
12.
Clin J Oncol Nurs ; 12(3): 445-54, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18515243

RESUMEN

Women diagnosed with stage III or IV ovarian cancer typically are treated with surgery followed by chemotherapy. Intraperitoneal (IP) chemotherapy, the direct administration of chemotherapy into the IP cavity, has been explored as a viable treatment option for some women with advanced ovarian cancer. Fatigue may occur as a result of the disease process, treatment, or a wide variety of physical, psychological, or situational factors. Fatigue is one of the most common and distressing side effects associated with chemotherapy and it may be intensified in women receiving IP chemotherapy. The purpose of this article is to examine fatigue in women receiving IP chemotherapy for advanced ovarian cancer and to examine what aspects of IP chemotherapy may contribute to fatigue development. Factors reviewed include surgery for debulking the tumor and placement of the IP catheter, administration of IV chemotherapy in addition to IP chemotherapy, pain, anemia, sleep disturbances, gastrointestinal disturbances, and emotional distress. Oncology nurses who are knowledgeable about the factors that contribute to fatigue in women receiving IP chemotherapy will be better prepared to conduct a comprehensive assessment and develop effective treatment strategies.


Asunto(s)
Antineoplásicos/efectos adversos , Fatiga/etiología , Inyecciones Intraperitoneales/efectos adversos , Enfermería Oncológica/organización & administración , Neoplasias Ováricas/complicaciones , Neoplasias Ováricas/terapia , Anemia/complicaciones , Antineoplásicos/administración & dosificación , Terapia Combinada , Medicina Basada en la Evidencia , Fatiga/diagnóstico , Fatiga/prevención & control , Femenino , Enfermedades Gastrointestinales/complicaciones , Humanos , Inyecciones Intraperitoneales/enfermería , Tamizaje Masivo , Estadificación de Neoplasias , Rol de la Enfermera , Evaluación en Enfermería , Neoplasias Ováricas/diagnóstico , Neoplasias Ováricas/epidemiología , Ovariectomía , Dolor/complicaciones , Factores de Riesgo , Trastornos del Sueño-Vigilia/complicaciones , Estrés Psicológico/complicaciones , Tasa de Supervivencia
13.
Eur J Pharm Sci ; 115: 362-368, 2018 Mar 30.
Artículo en Inglés | MEDLINE | ID: mdl-29410031

RESUMEN

Vaccines typically come with adjuvants that trigger the innate immune system in order to prepare best possible inflammatory conditions as to allow the adaptive immune system to become activated, generally for the induction of antibodies. The oldest approved and most abundant immunological adjuvants are salts of aluminium, which are also frequently used in animal models of immunisation and allergy desensitization. In rodents, the intraperitoneal administration of aluminium adjuvants is commonly performed and considered safe. In the current investigation, we show that intraperitoneal administration of aluminium adjuvants is associated with a dose-dependent hypothermic reaction within 10 min of the injection. The body temperature of mice dropped as much as 4 °C, and the clinical symptoms included apathy, hunched posture, and piloerection. The temperature normalised and other clinical manifestations disappeared within 60-80 min of the intraperitoneal aluminium injection, which caused strong infiltration of neutrophil and eosinophil granulocytes into the peritoneal cavity, a clinical manifestations typically associated with inflammasome activation. However, the observed reactions to aluminium adjuvants were independent of NALP3, caspase-1, and interleukin-1ß, but dependent on histamine. Hence, aluminium adjuvants may have potential local and systemic side effects, which warrants further investigations into the nature of these side effects, but also into the possible implications on health in man.


Asunto(s)
Adyuvantes Inmunológicos/efectos adversos , Adyuvantes Farmacéuticos/administración & dosificación , Aluminio/efectos adversos , Vacunas/efectos adversos , Aluminio/administración & dosificación , Aluminio/inmunología , Animales , Anticuerpos/inmunología , Femenino , Inmunización/efectos adversos , Inyecciones Intraperitoneales/efectos adversos , Interleucina-1beta/inmunología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Vacunación/efectos adversos , Vacunas/inmunología
14.
J Invest Surg ; 31(4): 321-327, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28557569

RESUMEN

BACKGROUND: Closed hyperthermic intraperitoneal chemotherapy (HIPEC) may increase abdominal pressure and effects of hemodynamic changes due to maintenance hyperthermia. Our aim was to analyze the safety and effectiveness of our closed technique with CO2 circulation in management fluid status and hemodynamic parameters by means of cardiac preload control measured by Global End Diastolic Values (GEDV) and a gas exchanger. MATERIAL AND METHODS: A Pilot Clinical Study that included 18 advanced ovarian cancer patients undergoing citoreductive surgery and HIPEC. We used a closed-perfusion system (PRS Combat®) that includes CO2 circulation and a gas exchanger. Transpulmonary thermodilutions and hemodynamic measurements (PiCCO2®) were performed after citoreductive surgery (Pre-HIPEC); At half time of the HIPEC (Intra-HIPEC); After HIPEC (Post-HIPEC). RESULTS: No significant hemodynamic measurements changes in the three thermodilutions values of Cardiac Index (CI) (p = 0.227), Global End Diastolic Values (GEVD) (p = 0.966), Stroke Volume Variation (SVV) (p = 0,884) and Systemic Vascular Resistance Index (SVRI) (p = 0.082). No correlation between central venous pressure (CVP) and GEDV (Pre-HIPEC: r = 0.164, p = 0.211; Intra-HIPEC: r = 0.015, p = 0.900; Post-HIPEC: r = 0.018, p = 0.890). There was better correlation between GEDV and CI (Pre-HIPEC: r = 0.432, p = 0.071; Intra-HIPEC: r = 0.418, p = 0.074; Post-HIPEC: r = 0.411, p = 0.080). CONCLUSIONS: Closed intrabdominal chemotherapy with CO2 circulation model may be a safe model for HIPEC by means of a gas exchanger. GEDV and its changes significantly correlated to CI, and not observed for CVP. GEDV values may be more appropriate for monitoring cardiac preload, blood loss limitation and to predict changes in intravascular volume status during intraperitoneal chemotherapy.


Asunto(s)
Presión Venosa Central , Fluidoterapia/métodos , Hipertermia Inducida/efectos adversos , Neoplasias Peritoneales/terapia , Volumen Sistólico , Adulto , Anciano , Anciano de 80 o más Años , Dióxido de Carbono/administración & dosificación , Procedimientos Quirúrgicos de Citorreducción , Femenino , Humanos , Hipertermia Inducida/instrumentación , Hipertermia Inducida/métodos , Inyecciones Intraperitoneales/efectos adversos , Inyecciones Intraperitoneales/métodos , Persona de Mediana Edad , Perfusión/efectos adversos , Perfusión/instrumentación , Perfusión/métodos , Proyectos Piloto
15.
Neurosci Lett ; 418(2): 175-80, 2007 May 17.
Artículo en Inglés | MEDLINE | ID: mdl-17418947

RESUMEN

3-Nitropropionic acid (3-NP), an irreversible inhibitor of succinate dehydrogenase, produces selective lesions in striatal neurons that resemble those observed in Huntington's disease neuropathology. In this study, we evaluated the role of peripheral bone marrow-derived cells (BMDCs) in the 3-NP-induced striatal damage by transplanting bone marrow cells with human SOD1 G93A mutation (mSOD1(G93A)) which induces amyotrophic lateral sclerosis through an unknown gain of toxicity and mitochondrial dysfunction. We assessed striatal damage after 3-NP treatment in the recipient C57BL/6 wild-type (WT) mice that received bone marrow cells from WT or mSOD1(G93A) transgenic donor mice (WT-->WT or mSOD(G93A)-->WT). After intraperitoneal injection of 3-NP, six of the eight mSOD1(G93A)-->WT mice had bilateral striatal lesions while only one out of eight WT-->WT mice had a striatal lesion. The lesion volume was significantly higher in the mSOD1(G93A)-->WT mice than in the WT-->WT mice. However, following an intrastriatal injection of 3-NP, there was no significant difference in the lesion volumes between the WT-->WT mice and mSOD1(G93A)-->WT mice. Thus, the exacerbation of 3-NP-induced striatal damage in mSOD(G93A)-->WT mice was only seen after systemic administration of 3-NP, but not after intrastriatal injection. These results demonstrate that altered SOD1 activity (mSOD(G93A)) in BMDCs affects striatal damage probably through a mechanism involving a systemic factor.


Asunto(s)
Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/metabolismo , Degeneración Nerviosa/inducido químicamente , Degeneración Nerviosa/genética , Nitrocompuestos/toxicidad , Propionatos/toxicidad , Superóxido Dismutasa/genética , Esclerosis Amiotrófica Lateral/genética , Esclerosis Amiotrófica Lateral/metabolismo , Esclerosis Amiotrófica Lateral/fisiopatología , Animales , Células de la Médula Ósea/enzimología , Trasplante de Médula Ósea , Cuerpo Estriado/fisiopatología , Predisposición Genética a la Enfermedad/genética , Humanos , Enfermedad de Huntington/inducido químicamente , Enfermedad de Huntington/enzimología , Enfermedad de Huntington/genética , Inyecciones Intraperitoneales/efectos adversos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Mutación/genética , Degeneración Nerviosa/fisiopatología , Neurotoxinas , Estrés Oxidativo/genética , Superóxido Dismutasa-1 , Quimera por Trasplante
16.
Drug Res (Stuttg) ; 67(12): 688-697, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-28847021

RESUMEN

Background Intraperitoneal drug administration applies treatment at the site of diseases with gynaecological, urological, or gastrointestinal origin. The objective of this systematic review was to investigate perioperative intraperitoneal administration of antibacterial agents to characterise the drugs used and their safety profile. Methods A protocol was registered at PROSPERO (CRD42016038956). A systematic review was conducted and reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). A search was performed in PubMed and EMBASE on the 22nd of April 2016. The inclusion criteria were original articles involving at least 5 patients where antibacterial agents were administered intraperitoneally during or after abdominal surgery as prophylaxis or treatment of infection. Languages were limited to English, German, Danish, Norwegian, or Swedish articles. Results 79 studies were included which used a total of 12 different antibacterial classes. Aminoglycosides, 1st and 2nd generation cephalosporins, tetracyclines, and penicillins were most commonly administered intraperitoneally during or after surgery. The antibacterial agent was usually administered intraperitoneally as monotherapy. However, some studies administered combination regimens with heparin or with another antibacterial agent. The most frequent combination was aminoglycosides and lincosamides. In total, 43% of studies lacked information regarding adverse events. The most frequently reported adverse event was discomfort or pain during administration, especially with use of oxytetracycline. Conclusion At least 12 different classes of antibacterial agents have been administered intraperitoneally during or after surgery as prophylaxis or treatment of intraabdominal infections. Intraperitoneal administration seems safe although use of oxytetracycline may cause discomfort or pain.


Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/efectos adversos , Inyecciones Intraperitoneales/efectos adversos , Atención Perioperativa/métodos , Antibacterianos/uso terapéutico , Humanos
17.
Antivir Ther ; 11(7): 935-9, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-17302257

RESUMEN

OBJECTIVE: Antiretroviral regimens containing the fusion inhibitor enfuvirtide (ENF) are associated with sustained viral suppression and immunological benefit. However, local injection site reactions (ISR) occur in the majority of patients. The aim of this study was to determine the pathogenesis of ISRs. METHODS: Injection sites were evaluated prospectively from 30 min up to 15-30 days post-injection in ENF-experienced (Cohort I) and ENF-naive patients (Cohort II) during the first 2 weeks of therapy. Four to five injections were given in rotating abdominal sites by a nurse using a standardized technique and were rigorously evaluated. RESULTS: Reactions were observed in 80-100% of patients; the majority of the reactions were mild to moderate, generally appeared within 24-48 h post-injection, and pain, induration and erythema were the most common clinical signs. Whereas most patients experienced ISRs, the overall prevalence in Cohort II was low (35% maximum). Punch biopsies of injection sites in Cohort I consisted primarily of mixed lymphocytic infiltrates with eosinophils and neutrophils. Injection vehicle (ENF buffer minus ENF) and reduced volume (2 x 0.5 ml ENF [45 mg] versus 1.0 ml [90 mg] ENF) were investigated in Cohort II. Fewer reactions appeared with vehicle and pain was absent with the smaller injection volume. Pathology was indistinguishable between ENF, vehicle and normal tissue in Cohort II patients. CONCLUSION: These results suggest that injection technique, injection volume and peptide may influence ISR to ENF.


Asunto(s)
Proteína gp41 de Envoltorio del VIH/efectos adversos , Inhibidores de Fusión de VIH/efectos adversos , Infecciones por VIH/patología , VIH-1 , Inyecciones Intraperitoneales/efectos adversos , Fragmentos de Péptidos/efectos adversos , Abdomen/patología , Adulto , Biopsia , Estudios de Cohortes , Enfuvirtida , Proteína gp41 de Envoltorio del VIH/administración & dosificación , Proteína gp41 de Envoltorio del VIH/uso terapéutico , Inhibidores de Fusión de VIH/administración & dosificación , Inhibidores de Fusión de VIH/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Humanos , Leucocitos/patología , Masculino , Persona de Mediana Edad , Dolor/etiología , Fragmentos de Péptidos/administración & dosificación , Fragmentos de Péptidos/uso terapéutico , Estudios Prospectivos , Factores de Tiempo
18.
J Pain ; 7(6): 408-16, 2006 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-16750797

RESUMEN

UNLABELLED: Pain increases the rate, frequency, or intensity of some behaviors (eg, withdrawal responses) and suppresses other behaviors (eg, feeding). Our laboratories are developing assays to test analgesic drug candidates using measurements of pain-suppressed rather than pain-elicited behaviors. Such assays may model important aspects of clinical pain and provide a means for distinguishing true analgesics from drugs that produce motor impairment. The present study compared effects of the mu opioid analgesic morphine and the nonanalgesic neuroleptic haloperidol on intraperitoneal acetic acid-induced writhing (a pain-elicited behavior) and suppression of feeding behavior (a pain-suppressed behavior). In feeding studies, C57BL/6J mice were given access to a dish containing 8 mL Ensure(trade mark) liquid food (0-100% in water) during daily sessions (7.5-120 min). Levels of consumption were dependent on both Ensure concentration and session duration. Intraperitoneal injection of acetic acid (0.10-0.56%) produced a time- and concentration-dependent decrease in Ensure consumption. Morphine (1 mg/kg) prevented both acid-induced writhing and acid-induced suppression of feeding, whereas the dopamine antagonist haloperidol inhibited writhing without preventing acid-induced suppression of feeding. The effects of morphine were time-dependent, selective for acid-suppressed feeding, and naltrexone-reversible. These results suggest that assays of pain-suppressed behaviors may complement assays of pain-elicited behaviors in preclinical studies of candidate analgesics. PERSPECTIVE: This paper presents a new preclinical strategy for assessing pain and analgesia in mice that is congruent with current methods of pain assessment in the clinic. This strategy may therefore be a useful complement to more traditional procedures for assessing pain and analgesia.


Asunto(s)
Conducta Animal/efectos de los fármacos , Conducta Alimentaria/efectos de los fármacos , Morfina/farmacología , Dimensión del Dolor/métodos , Dolor/tratamiento farmacológico , Ácido Acético/efectos adversos , Analgésicos Opioides/farmacología , Animales , Conducta Animal/fisiología , Modelos Animales de Enfermedad , Antagonistas de Dopamina/farmacología , Evaluación Preclínica de Medicamentos/métodos , Interacciones Farmacológicas , Conducta Alimentaria/fisiología , Haloperidol/farmacología , Inyecciones Intraperitoneales/efectos adversos , Masculino , Ratones , Ratones Endogámicos C57BL , Antagonistas de Narcóticos/farmacología , Dolor/inducido químicamente , Dolor/fisiopatología , Dimensión del Dolor/efectos de los fármacos , Valor Predictivo de las Pruebas , Receptores Opioides mu/efectos de los fármacos , Receptores Opioides mu/metabolismo , Factores de Tiempo
19.
Dis Aquat Organ ; 69(2-3): 239-48, 2006 Apr 06.
Artículo en Inglés | MEDLINE | ID: mdl-16724568

RESUMEN

In August 1998, 3000 Atlantic salmon Salmo salar L. parr were divided into 7 groups with 2 replicates. Every 6 wk until March of the following year 1 group was vaccinated. One group was held as an unvaccinated control. The fish were transferred to seawater in May 1999, and slaughtered in February 2000. Temperature, fish size and photoperiod at vaccination, and the time between vaccination and sea transfer thus varied among the groups. In all vaccinated groups, growth was reduced for 1 to 2 mo following vaccination. Intra-abdominal lesions developed faster, and stabilised at a higher level in the groups vaccinated early at the highest temperature and the smallest fish size. Growth in seawater was influenced by the time of vaccination. At the end of the experiment, the group vaccinated last (MAR) was the heaviest of the vaccinated groups (4.0 kg), and the group vaccinated first, i.e. in August (AUG) was smallest (3.2 kg). Growth rate in seawater differed only in the summer when specific growth rate was above 1.45 in all groups. There was a correlation between adhesion, condition factor and number of weeks from vaccination to sea transfer. The AUG group had the highest condition factor, with a top level of 1.64 in autumn, and this group also displayed the highest incidence of deformed vertebra. The experiment shows that side effects of vaccination can be significantly reduced when planning the vaccination strategy, by taking environmental factors and fish biology into consideration.


Asunto(s)
Enfermedades Peritoneales/veterinaria , Salmo salar/crecimiento & desarrollo , Salmo salar/inmunología , Columna Vertebral/anomalías , Vacunación/veterinaria , Aeromonas salmonicida/inmunología , Aliivibrio salmonicida/inmunología , Animales , Anticuerpos Antibacterianos/sangre , Tamaño Corporal , Forunculosis/prevención & control , Forunculosis/veterinaria , Inyecciones Intraperitoneales/efectos adversos , Inyecciones Intraperitoneales/veterinaria , Enfermedades Peritoneales/etiología , Enfermedades Peritoneales/patología , Agua de Mar , Columna Vertebral/patología , Estadística como Asunto , Temperatura , Factores de Tiempo , Adherencias Tisulares/veterinaria , Tomografía Computarizada por Rayos X/veterinaria , Vacunación/efectos adversos
20.
Lab Anim ; 50(4): 264-74, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-26860578

RESUMEN

Injection anaesthesia is commonly used in laboratory mice; however, a disadvantage is that post-anaesthesia recovery phases are long. Here, we investigated the potential for shortening the recovery phase after injection anaesthesia with fentanyl-midazolam-medetomidine by antagonization with naloxone-flumazenil-atipamezole. In order to monitor side-effects, the depth of anaesthesia, heart rate (HR), core body temperature (BT) and concentration of blood gases, as well as reflex responses, were assessed during a 50 min anaesthesia. Mice were allowed to recover from the anaesthesia in their home cages either with or without antagonization, while HR, core BT and spontaneous home cage behaviours were recorded for 24 h. Mice lost righting reflex at 330 ± 47 s after intraperitoneal injection of fentanyl-midazolam-medetomidine. During anaesthesia, HR averaged 225 ± 23 beats/min, respiratory rate and core BT reached steady state at 131 ± 15 breaths/min and 34.3 ± 0.25℃, respectively. Positive pedal withdrawal reflex, movement triggered by tail pinch and by toe pinch, still occurred in 25%, 31.2% and 100% of animals, respectively. Arterial blood gas analysis revealed acidosis, hypoxia, hypercapnia and a marked increase in glucose concentration. After anaesthesia reversal by injection with naloxone-flumazenil-atipamezole, animals regained consciousness after 110 ± 18 s and swiftly returned to physiological baseline values, yet they displayed diminished levels of locomotion and disrupted circadian rhythm. Without antagonization, mice showed marked hypothermia (22 ± 1.9℃) and bradycardia (119 ± 69 beats/min) for several hours. Fentanyl-midazolam-medetomidine provided reliable anaesthesia in mice with reasonable intra-anaesthetic side-effects. Post-anaesthetic period and related adverse effects were both reduced substantially by antagonization with naloxone-flumazenil-atipamezole.


Asunto(s)
Anestésicos Combinados/farmacología , Fentanilo/farmacología , Medetomidina/farmacología , Midazolam/farmacología , Atención Perioperativa , Analgésicos/efectos adversos , Analgésicos/farmacología , Anestésicos Combinados/efectos adversos , Animales , Temperatura Corporal/efectos de los fármacos , Femenino , Fentanilo/efectos adversos , Fentanilo/antagonistas & inhibidores , Flumazenil/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Imidazoles/farmacología , Inyecciones Intraperitoneales/efectos adversos , Medetomidina/efectos adversos , Medetomidina/antagonistas & inhibidores , Ratones , Ratones Endogámicos C57BL , Midazolam/efectos adversos , Midazolam/antagonistas & inhibidores , Naloxona/farmacología , Antagonistas de Narcóticos/farmacología , Neurotransmisores/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA